You’re reading a free stock page from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More
Moderna Returns vs. S&P
|1 Year||5 Year||5 Year Annualized||Since IPO|
Moderna Company Info
News & Analysis
These stocks all fell by double digits last year.
The company is starting the year on a strong note.
Moderna stock has dropped 60% from its peak.
Here are the five best biotech ETFs to invest in right now.
The company could soon have a new vaccine bringing in revenue.
Moderna could follow closely behind Pfizer and GSK in entering the lucrative RSV vaccine market.
The Nasdaq looked poised for modest gains once again on Wednesday.
Moderna's vaccine earnings are helping it prepare for the future.
Microsoft CEO Satya Nadella talked about his company's doubling down on gaming, which should give gamers and investors pause.
Moderna has got some promising news on the coronavirus vaccine front.
Moderna shares got a boost as the company continued its COVID-19 vaccine trials.
Encouraging news coming out of the biotech regarding its coronavirus vaccine candidate caused its stock to pop.
MRNA earnings call for the period ending September 30, 2022.
MRNA earnings call for the period ending June 30, 2022.
MRNA earnings call for the period ending December 31, 2021.
MRNA earnings call for the period ending September 30, 2021.
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.